Member Info for Hurst10

Would expect proper size buying later this morning, through 160p coming into NY AM.

Will press on to test year high.

The majors are getting ready.

So far we are up 50% since spring, keep buying.

This company is being re rated before one of the majors does it for them.

Tomorrow at noon , impossible to get stock pre NY hrs

Hope you are all on board .

Dr Fiona will be talking about AVA 3996 etc growing at pace. As expected the share price has only begun to reflect the vast upside which is out there!

Wait for revised numbers on Thursday!

With Biotech sector up and running with M&A on almost daily basis, having Avacta presenting at AACR twice and as we know now, it is the whole AVA platform, which Avacta will also discuss and the market will quickly understand the potential magnitude of the whole precision oncology market, as will the majors !

Breaking 6 month highs- NY will have to pay 150, with very little stock around.

Come Thursday presentation/ update we are going north fast!

With the Conference starting Wednesday the 11th, one would assume that Tuesday the 10th will be pre conference day, with all the majors arriving and the same for the speakers and indeed Avacta with their first presentation due at midday Thursday, hence a license deal could very likely be announced tomorrow.

Post market prints could show size and price above current level.

And ESMO next week in Madrid!

With the Dow open on Columbus Day, we should see size buyers stepping in before the conference, joining Precision Oncology, before Novartis, Roche or BMY does it for them.

Thanks.

Next week early coffee’s in NY, will be good!

In view of what will be a very upbeat presentation y Avacta in Boston, “ AVA6000 at pace “ and AVA3996 + AVA032 “ The data to be presented showcases the potential of our two therapeutic platforms to generate further high value clinical assets.”

One would expect further keen size buyers this afternoon, trusting a License deal to be announced next week prior to the presentation in Boston and ESMO in Madrid the following week.

French pharmaceutical giant Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics, according to people familiar with the matter. Mirati’s shares surged 45% — the most since 2017 — in New York trading.

Worth remembering that following the AACR conference in the US, we have the ESMO oncology conference in Madrid on the 20-24/10, with all the majors attending.

Excellent timing for Avacta having presented at the ACCR conference.

One of the majors presenting on Precision Oncology:

Friday:

Bayer - Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients’ Lives.

As mentioned before, this year’s ESMO conference will be dominated by precision oncology and M&A .

Thanks.

Daewoong link points out a translation facility ?

Jacob Van Naarden, who runs Lilly’s oncology unit, described the acquisition as the “beginning” of his company’s investment in developing “multiple meaningful radioligand medicines for hard-to-treat cancers.”

Following Eli Lilly’s acquisition of Point Biopharma and Avacta’s exposure to that transaction, worth reminding ourselves that we ESMO 2023 later this month, October 20-24/10,The ESMO Congress is a highly influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

ESMO 2023 will work towards the dissemination of the latest data, provide high quality education and excellent networking opportunities for oncologists and other stakeholders from all around the world.

Bayer presenting on Precision Oncology on 20/10. The conference will only highlight the investment case for Avacta.

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

JT, I agree with some of your views, however I personally believe there is already a license deal in place with a major, hence the CEO’s answer to the question regarding working capital” would not worry about that “, hence the of group of majors who would be interested, have no doubt worked out, which of the large cap Pharma’s won the bidding war and we will no doubt have that RNS very soon. This will of course accelerate the process of a Therapeutic IPO state side and also change the structure of the shareholder list significantly in favour of a 90/10 % institutional vs retail.

To be able to pick up stock at current levels is very much Christmas arrived early.

Size buyers will step up the pace, before it is too late.